Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving therapy (BCT). Several clinical risk factors are associated with local recurrence (LR) after BCT but are unable to explain all instances of LR after BCT. Here, gene expression microarrays are used to identify novel risk factors for LR after BCT. Experimental Design: Gene expression profiles of 56 primary invasive breast carcinomas from patients who developed a LR after BCT were compared with profiles of 109 tumors from patients who did not develop a LR after BCT. Both unsupervised and supervised methods of classification were used to separate patients into groups corresponding to disease outcome. In addition, for 15 patients, the gene express...
Prognostic markers; Tumour biomarkersMarcadores pronósticos; Biomarcadores tumoralesMarcadors pronòs...
Cyclophosphamide, methotrexate and 5-fluorouracile (CMF)-based chemotherapy for adjuvant treatment o...
PURPOSE: Women with hormone receptor-positive early breast cancers have a persistent risk of relapse...
PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
PURPOSE: A gene expression signature, predictive for local recurrence after breast-conserving treatm...
IntroductionTo tailor local treatment in breast cancer patients there is a need for predicting ipsil...
Purpose: To investigate risk factors for local recurrence (LR) after breast conserving therapy in yo...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Introduction Some patients with breast cancer develop local recurrence after breast-conservation sur...
This study aims to explore gene expression profiles that are associated with locoregional (LR) recur...
MOTIVATION: In recent years, microarray technology has revealed many tumor-expressed genes prognosti...
We previously identified 34 genes of interest (GOI) in 2006 to aid the oncologists to determine whet...
Introduction: Breast cancer risk of recurrence is known to span 20 years, yet existing prognostic si...
AbstractWe previously identified 34 genes of interest (GOI) in 2006 to aid the oncologists to determ...
Prognostic markers; Tumour biomarkersMarcadores pronósticos; Biomarcadores tumoralesMarcadors pronòs...
Cyclophosphamide, methotrexate and 5-fluorouracile (CMF)-based chemotherapy for adjuvant treatment o...
PURPOSE: Women with hormone receptor-positive early breast cancers have a persistent risk of relapse...
PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
Purpose: The majority of patients with early-stage breast cancer are treated with breast-conserving ...
PURPOSE: A gene expression signature, predictive for local recurrence after breast-conserving treatm...
IntroductionTo tailor local treatment in breast cancer patients there is a need for predicting ipsil...
Purpose: To investigate risk factors for local recurrence (LR) after breast conserving therapy in yo...
The 70-gene signature (MammaPrint (TM)) has been developed to predict the risk of distant metastases...
Introduction Some patients with breast cancer develop local recurrence after breast-conservation sur...
This study aims to explore gene expression profiles that are associated with locoregional (LR) recur...
MOTIVATION: In recent years, microarray technology has revealed many tumor-expressed genes prognosti...
We previously identified 34 genes of interest (GOI) in 2006 to aid the oncologists to determine whet...
Introduction: Breast cancer risk of recurrence is known to span 20 years, yet existing prognostic si...
AbstractWe previously identified 34 genes of interest (GOI) in 2006 to aid the oncologists to determ...
Prognostic markers; Tumour biomarkersMarcadores pronósticos; Biomarcadores tumoralesMarcadors pronòs...
Cyclophosphamide, methotrexate and 5-fluorouracile (CMF)-based chemotherapy for adjuvant treatment o...
PURPOSE: Women with hormone receptor-positive early breast cancers have a persistent risk of relapse...